Related Experiment Videos
Piperacillin/tazobactam therapy for diabetic foot infection
A M Zeillemaker1, K E Veldkamp, M G van Kraaij
1Department of Surgery, Diakonessen Hospital, Utrecht, The Netherlands.
Foot & Ankle International
|May 30, 1998
Summary
Piperacillin/tazobactam effectively treated diabetic foot infections in most patients, achieving clinical improvement or cure. While side effects occurred, the antibiotic showed promise for monotherapy in managing this common complication.
Area of Science:
- Infectious Diseases
- Pharmacology
- Diabetology
Background:
- Diabetic foot infections are a significant cause of morbidity and limb loss.
- Effective antibiotic management is crucial for favorable outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin/tazobactam as monotherapy for diabetic foot infections.
Main Methods:
- A prospective study involving 29 hospitalized patients with diabetic foot infections.
- Treatment administered: piperacillin/tazobactam.
- Efficacy assessed in 23 patients; adverse events monitored in all.
Main Results:
- 22 out of 23 evaluated patients (96%) showed improvement or clinical cure.
- Persistence of baseline pathogens was observed in 7 patients (30%).
- Adverse events occurred in 15 patients (58%), with 3 serious events.
Conclusions:
- Piperacillin/tazobactam demonstrates efficacy and an acceptable safety profile for diabetic foot infections.
- It may serve as a valuable monotherapy option, comparable to other broad-spectrum antibiotics.